ED
KYMR icon

Exane Derivatives’s Kymera Therapeutics KYMR Stock Holding History

Exane Derivatives’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,301
Closed -$50.6K – 1068
2021
Q1 		$50.6K Buy
+1,301
New +$78.3K 0.01% 514

Other funds holding KYMR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Exane Derivatives's KYMR Position: Q2 2021 in Review

Exane Derivatives sold out of Kymera Therapeutics (KYMR) in Q2 2021, closing a stake of 1,301 shares — an estimated $50.6K sold.

Exane Derivatives first reported a position in KYMR in Q1 2021 and held it in 1 quarter. The position peaked at $50.6K in Q1 2021. 110 funds tracked by Wall St. Rank hold KYMR as of Q2 2021.

  • Exane Derivatives reported no remaining Kymera Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,301 Kymera Therapeutics shares in Q2 2021, an estimated $50.6K.
  • Exane Derivatives first reported a position in Kymera Therapeutics in Q1 2021 and held it in 1 quarter.
  • Exane Derivatives's Kymera Therapeutics position peaked at $50.6K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.